NCT00820417已完成1 期
Phase 1 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of the Combination of Cetuximab (C-225), a Chimeric Monoclonal Antibody Against the Epidermal Growth Factor Receptor (EGFR), and Gefitinib (ZD1839), a Selective EGFR Tyrosine Kinase Inhibitor, in Patients With Advanced Cancer
Harrison Clinical Research2 个研究点 分布在 2 个国家目标入组 63 人开始时间: 2004年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 63
- 试验地点
- 2
- 主要终点
- The primary objective of the study is to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of the combination intravenous Cetuximab/oral Gefitinib.
研究概览
简要总结
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR. Primary objective is the determination of the maximum tolerated dose (MTD) and recommended dose (RD) of the combination of intravenous Cetuximab and oral Gefitinib.
详细描述
Between 36 and 66 patients will be enrolled depending on the number of dose levels which can be completed. Patients will have histologically confirmed EFGR-expressing solid malignant tumours (colorectal cancer, head and neck cancer and NSCLC), which did not respond to standard therapy or for which no suitable therapy exists.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent prior to inclusion
- •Confirmed histological diagnosis of non-resectable, solid, malignant, EGFR expressing tumours of the following types: colorectal cancer, head and neck cancer and non-small cell lung cancer (NSCLC). Advanced clinical stage III/IV which did not respond to standard therapy or for which no suitable therapy exists
- •Patients with at least one evaluable lesion (evaluable disease) by the RECIST criteria
- •Availability of tumour tissue, whether from primary tumour or metastasis to determine EGFR expression
- •Viability of establishing outpatient treatment
- •Effective contraception for patients of both sexes if there is a risk of conception
- •Karnofsky performance status greater than 70 %
- •Life expectancy > 12 weeks
- •Adequate renal function (creatinine < 1.5 x UNL), liver function (bilirubin < 1.5 x UNL, ALT/AST < 2.5 x UNL o <5 x UNL if hepatic metastasis) and adequate bone marrow (leucocytes > 3000/µl, absolute neutrophil count > 1500/µl, platelets > 100,000/µl, haemoglobin > 9 g/dl)
- •Patients must not have undergone chemotherapy, radiotherapy or major surgery during the 3 weeks before the beginning of the study, and they must have recovered from the relevant secondary effects of previous treatments
- •Patients agree to have a new biopsy after two weeks.
排除标准
- •Patients with any symptom of bowel obstruction and/or inflammatory bowel disease
- •Previous therapy with anti-EGFR drugs
- •Patients with known cerebral metastasis
- •Patients with known active and uncontrolled infections
- •Severe uncontrolled organic dysfunctions or metabolic disorders
- •Patients unable to give informed consent
- •Patients who do not wish to or who cannot undergo the specific study treatments and the study procedures
- •Pregnancy or breastfeeding
- •Patient participation in another clinical trial during the previous 30 days
- •Patients with known drug and/or alcohol abuse
- •Known hypersensitivity to chimeric MoAbs or pretreatment with MoAbs
- •Any other malignant tumour in the last two years or previously diagnosed malignant tumour if there is no guarantee that it is under complete control, except for suitably treated in situ cervical carcinoma or basocellular carcinoma
- •Known severe hypersensitivity to ZD1839 or any of the excipients of this product
- •Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not to be excluded)
- •Any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2 from previous anticancer therapy
- •Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort
研究组 & 干预措施
a
Experimental
Dose-escalation
干预措施: Cetuximab/Gefitinib combination and/or monotherapy (Drug)
B
Experimental
Maximum tolerated dose (MTD)
干预措施: Cetuximab/Gefitinib combination and/or monotherapy (Drug)
结局指标
主要结局
The primary objective of the study is to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of the combination intravenous Cetuximab/oral Gefitinib.
次要结局
- To determine the pharmacokinetic (PK) parameters of the combination Cetuximab/Gefitinib
- To determine the pharmacogenomic profile of study patients and to correlate the different profiles with efficacy
- To determine the possible correlation between activity and the polymorphisms of the EGFR measured in the blood and in the primary tumour
- To assess the possible immune response related to cetuximab
- To estimate signs of clinical activity (response rate according to the RECIST criteria)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)ObesityNCT06279234Pfizer50
已完成
1 期
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal ImpairmentRenal ImpairmentNCT04646889Arthrosi Therapeutics46
终止
1 期
Study Evaluating Betrixaban in Pediatric ParticipantsVTE ProphylaxisNCT03346083Alexion Pharmaceuticals, Inc.21
已完成
1 期
Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy SubjectsHealthy VolunteersNCT04073589argenx33
已完成
1 期
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.HealthyNCT06532383Pfizer22